/
Ophthalmology
Age-Related Macular Degeneration
50
Pipeline Programs↗
116
Active Trials↗
82
Companies Involved↗
Age-Related Macular Degeneration is a moderately active landscape with 50 programs across 82 companies. The most active players are Chengdu Origen Biotechnology Co., Ltd., Astellas, 4D Molecular Therapeutics. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Phase 111
Phase 215
Phase 38
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
32 of 36 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 36 classified programs, each share of the total. Modality classified for 86% of 50 pipeline programs.
Analysis
Trial Status
480
clinical trials
Completed264 · 55%
Recruiting60 · 13%
Terminated49 · 10%
Active, not recruiting37 · 8%
Unknown status34 · 7%
Not yet recruiting17 · 4%
Other19 · 4%
Clinical Trials
Trial Activity
480 trials
Page 1 of 32
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)